A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to examine the effect of pramlintide on body weight and its safety and tolerability in obese subjects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Islet Amyloid Polypeptide; Pramlintide

Criteria

Inclusion Criteria:

• Is obese with a body mass index (BMI) >=30 kg/m^2 to <=50 kg/m^2, and has been obese for at least one year before screening.

• Usually consumes at least three major meals (morning, midday, and evening) each day.

Exclusion Criteria:

• Is currently enrolled in a formal weight-loss program.

• Has had liposuction within 1 year before screening or is planning to have liposuction during the study.

• Has received any investigational drug within 3 months before screening.

• Has previously participated in a study using pramlintide.